Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Masafumi Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6196-8643; OpenAlex author ID A5017008069, A5123746698. Sources: OpenAlex.

Their work

Papers
70 (first author 3, last author 36)
Trials
0
Grants
0
Labs led
1
Collaborators
192
Papers, trials and grants by year

2012: 3 papers · 2013: 3 papers · 2014: 2 papers · 2015: 3 papers · 2016: 5 papers · 2017: 6 papers · 2018: 4 papers · 2019: 4 papers · 2020: 9 papers · 2021: 10 papers · 2022: 4 papers · 2023: 4 papers · 2024: 8 papers · 2025: 2 papers · 2026: 3 papers

Papers 50 of 70

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
  2. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. First author DOI 10.1097/mpa.0000000000002600↗
  3. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  4. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  5. Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. Last author DOI 10.21873/anticanres.17792↗
  6. Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy. Co-author DOI 10.1038/s41598-024-65093-2↗
  7. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  8. Immature stroma and high infiltration of CD15+ cells are predictive markers of poor prognosis in different subsets of patients with pancreatic cancer. Co-author DOI 10.1111/cas.16060↗
  9. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Last author DOI 10.1158/0008-5472.can-24-0830↗
  10. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-24-1004↗
  11. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  12. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. Last author DOI 10.1186/s13046-024-03060-5↗
  13. [Microbiome in the Therapy for the Pancreatic Cancer]. Last author PMID 39009514↗
  14. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Last author DOI 10.1007/s00432-022-04554-5↗
  15. Minimally invasive distal pancreatectomy for pancreatic cancer: cranial-to-caudal approach with identification of Gerota's fascia (with video). Last author DOI 10.1007/s00464-023-10438-7↗
  16. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. Last author DOI 10.1007/s11605-023-05591-2↗
  17. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Last author DOI 10.1111/cas.15901↗
  18. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s12672-021-00462-1↗
  19. Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer. Co-author DOI 10.1186/s12885-022-10207-0↗
  20. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Last author DOI 10.1186/s13046-022-02301-9↗
  21. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer. Last author DOI 10.3390/cancers14163994↗
  22. Minimally invasive surgery for pancreatic cancer. Last author DOI 10.1007/s00595-020-02120-5↗
  23. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Last author DOI 10.1007/s00595-020-02123-2↗
  24. Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrine neoplasm type 1. Co-author DOI 10.1007/s12328-020-01234-0↗
  25. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Last author DOI 10.1016/j.canlet.2021.04.013↗
  26. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Co-author DOI 10.1016/j.cell.2021.07.020↗
  27. PIK3CB is involved in metastasis through the regulation of cell adhesion to collagen I in pancreatic cancer. Last author DOI 10.1016/j.jare.2021.02.002↗
  28. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Last author DOI 10.1016/j.pan.2021.04.002↗
  29. The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer. Co-author DOI 10.1111/cas.14858↗
  30. Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer. Co-author DOI 10.1177/1060028020969354↗
  31. Efficient pre-treatment for pancreatic cancer using chloroquine-loaded nanoparticles targeting pancreatic stellate cells. Last author DOI 10.3892/ol.2021.12894↗
  32. Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer? Last author DOI 10.1002/ags3.12340↗
  33. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neopla… Co-author DOI 10.1007/s00428-020-02844-2↗
  34. High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neo… Last author DOI 10.1007/s00595-019-01852-3↗
  35. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in… Co-author DOI 10.1097/sla.0000000000003060↗
  36. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Last author DOI 10.1371/journal.pone.0228015↗
  37. Early Detection of Pancreatic Cancer: Role of Biomarkers in Pancreatic Fluid Samples. Co-author DOI 10.3390/diagnostics10121056↗
  38. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Last author DOI 10.3892/ijo.2019.4951↗
  39. FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients. Co-author DOI 10.7150/jca.38399↗
  40. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Last author DOI 10.7150/thno.47001↗
  41. An In Vitro Three-Dimensional Organotypic Model to Analyze Peripancreatic Fat Invasion in Pancreatic Cancer: A Culture System Based on Collagen Gel Embedding. Last author DOI 10.1007/978-1-4939-8879-2_11↗
  42. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Last author DOI 10.1007/s00423-019-01754-5↗
  43. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Last author DOI 10.1016/j.canlet.2018.12.005↗
  44. S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. Last author DOI 10.3892/ijo.2019.4812↗
  45. Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. Last author DOI 10.1016/j.canlet.2017.10.010↗
  46. Multicenter study of early pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2017.11.007↗
  47. Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pa… Last author DOI 10.1016/j.surg.2017.09.040↗
  48. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  49. Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence. Last author DOI 10.1007/s00268-017-4068-6↗
  50. Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. Last author DOI 10.1016/j.pan.2017.08.009↗

Closest collaborators

The 25 strongest of 192 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 32 shared papers, 2017–2026 · strength 4.39
  2. Kenoki Ohuchida · 37 shared papers, 2012–2024 · strength 3.96
  3. Takao Ohtsuka · 38 shared papers, 2012–2026 · strength 3.21
  4. Yoshinao Oda · 27 shared papers, 2014–2025 · strength 2.88
  5. Naoki Ikenaga · 16 shared papers, 2021–2026 · strength 2.52
  6. Yoshihiro Miyasaka · 22 shared papers, 2016–2025 · strength 2.12
  7. Toshiya Abe · 17 shared papers, 2017–2026 · strength 2.11
  8. Chika Iwamoto · 13 shared papers, 2017–2024 · strength 1.58
  9. Noboru Ideno · 12 shared papers, 2013–2025 · strength 1.45
  10. Yasuhisa Mori · 13 shared papers, 2013–2026 · strength 1.30
  11. Tomohiko Shinkawa · 7 shared papers, 2020–2024 · strength 1.09
  12. Koji Shindo · 10 shared papers, 2015–2024 · strength 1.07
  13. Kazuhiro Koikawa · 10 shared papers, 2017–2024 · strength 0.88
  14. Masataka Hayashi · 5 shared papers, 2023–2024 · strength 0.86
  15. Takashi Okumura · 11 shared papers, 2016–2021 · strength 0.83
  16. Akiko Sagara · 7 shared papers, 2017–2024 · strength 0.74
  17. Shin Kibe · 8 shared papers, 2017–2023 · strength 0.69
  18. Ryota Matsuda · 6 shared papers, 2020–2021 · strength 0.66
  19. Koki Oyama · 4 shared papers, 2022–2024 · strength 0.61
  20. Pingshan Zhong · 4 shared papers, 2021–2024 · strength 0.58
  21. Yohei Ando · 7 shared papers, 2017–2021 · strength 0.55
  22. Nao Fujimori · 4 shared papers, 2021–2023 · strength 0.55
  23. Biao Zheng · 7 shared papers, 2015–2021 · strength 0.50
  24. Shin Takesue · 7 shared papers, 2017–2020 · strength 0.50
  25. Sho Endo · 7 shared papers, 2017–2021 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.